Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524706 | 0.94 | F10 (0.34) | F10CA1CA2POLBP2RX7 | |
| SCHEMBL2524696 | 0.93 | MTOR (0.34) | F10CA1CA2POLBEPHX2 | |
| SCHEMBL14234758 | 0.93 | F10 (0.35) | F10CA1CA2POLBP2RX7 | |
| SCHEMBL2521287 | 0.92 | F10 (0.34) | F10CA1CA2POLBEPHX2 | |
| SCHEMBL14685933 | 0.91 | P2RX7 (0.32) | F10CA1CA2P2RX7EPHX2 | |
| SCHEMBL2522212 | 0.91 | LMNA (0.36) | — | |
| SCHEMBL2516410 | 0.88 | PDE3B (0.36) | — | |
| SCHEMBL2518670 | 0.88 | EPHX2 (0.38) | POLBP2RX7EPHX2MAPTTRPA1 | |
| SCHEMBL2523120 | 0.87 | MTOR (0.34) | F10CA1CA2POLBL3MBTL1 | |
| SCHEMBL27911083 | 0.85 | CA1 (0.31) | F10CA1CA2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556060-A1 | SUBSTITUTED 3,5- DIPHENYL-ISOXAZOLINE DERIVATIVES AS INSECTICIDES AND ACARICIDES | AH USA 42 LLC (US) | 2013-02-13 | — | — | EP | claimed |
| CN-102933563-A | Substituted 3,5-di phenyl-isoxazoline derivatives as insecticides and acaricides | AH US 42 CO LTD | 2013-02-13 | — | — | CN | claimed |
| WO-2011124998-A1 | SUBSTITUTED 3,5- DI PHENYL - ISOXAZOLINE DERIVATIVES AS INSECTICIDES AND ACARICIDES | PFIZER INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110251247-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | PFIZER INC. (US) | 2011-10-13 | — | — | US | claimed |
| EP-2556060-A1 | SUBSTITUTED 3,5- DIPHENYL-ISOXAZOLINE DERIVATIVES AS INSECTICIDES AND ACARICIDES | AH USA 42 LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| CN-102933563-A | Substituted 3,5-di phenyl-isoxazoline derivatives as insecticides and acaricides | AH US 42 CO LTD | 2013-02-13 | — | — | CN | disclosed |
| WO-2011124998-A1 | SUBSTITUTED 3,5- DI PHENYL - ISOXAZOLINE DERIVATIVES AS INSECTICIDES AND ACARICIDES | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011124998-A1 | SUBSTITUTED 3,5- DI PHENYL - ISOXAZOLINE DERIVATIVES AS INSECTICIDES AND ACARICIDES | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251247-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | PFIZER INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251247-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | PFIZER INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251247-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | PFIZER INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251247-A1 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | CYP4X1, COL1A1, RDX | F10 1451/4885CA1 2771/4885CA2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.